Phase 2 N=6 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Anaplastic Thyroid Cancer
Primary: Overall Response (OR) — 0; 3; 3; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=10 A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
Thyroid Cancer
Primary: Change in Tumor Size — 4.7 cm
Phase 3 N=417 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Thyroid Neoplasms
Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001
N/A N=10 Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Papillary Thyroid Carcinoma
Primary: Increased Radioiodine Uptake — 6 Participants
Phase 2 N=9 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Thyroid Cancer · Anaplastic Thyroid Cancer · Undifferentiated Thyroid Cancer
Primary: Number of Participants With Overall Response (OR) — 0 Participants
Phase 2 N=55 Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Columnar Cell Variant Thyroid Gland Papillary Carcinoma · Follicular Variant Thyroid Gland Papillary Carcinoma · Metastatic Thyroid Gland Follicular Carcinoma
Primary: Complete Response Rate (Cohort 1) — 0 percentage of participants
Phase 2 N=3 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer · Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg
Phase 2 N=3 Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Primary: Overall Survival Rate — 0 percentage of participants alive
Phase 3 N=238 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
Differentiated Thyroid Cancer
Primary: Progression-Free Survival (PFS) — 10.0; 5.7 months — p=0.080
Phase 2 N=23 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Papillary Thyroid Cancer · Follicular Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Progression Free Survival — 241 days
Phase 2 N=53 Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Follicular Thyroid Cancer · Insular Thyroid Cancer · Papillary Thyroid Cancer
Primary: Overall Objective Response Rate, Defined as the Proportion of Patients Who Have a Minor Response (MR), Partial Response (PR), or Complete Response(CR)Assessed According…
Phase 2 N=12 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants
Phase 2 N=123 Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
Thyroid Gland Anaplastic Carcinoma
Primary: (Phase II) Overall Survival — 37.1; 29.0 percentage of participants — p=0.2831
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=145 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
Thyroid Neoplasms
Primary: Time to Tumor Progression — 334; 176 days
Phase 2 N=22 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Insular Thyroid Cancer · Recurrent Thyroid Cancer · Stage II Follicular Thyroid Cancer
Primary: Objective Tumor Response Rate Assessed by RECIST — 0 participants
Phase 2 N=63 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Thyroid Cancer
Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants
Phase 2 N=42 Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Thyroid Cancer
Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants
Phase 2 N=19 Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer · Recurrent Thyroid Cancer
Primary: Confirmed Response Rate (Partial Response [PR] or Complete Response [CR]) Per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 Criteria — 13 percentage of…
Phase 2 N=50 RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Thyroid Cancer
Primary: Median Progression Free Survival — 12.5 months
Phase 2 N=13 Trial of LBH589 in Metastatic Thyroid Cancer
Thyroid Carcinoma
Primary: Tumor Response Rate to LBH589. — 13; 0 participants
N/A N=5 Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
Papillary Thyroid Cancer · Papillary Thyroid Microcarcinoma
Primary: Changes in Thyroid Nodule Size — 0.241361; 0.954909; 0.422121; 0.104143 mL
Phase 2 N=9 A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
Solid Tumor · Anaplastic Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) of Cisplatin (Phase I) — 100 mg/m^2
Phase 2 N=60 Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Thyroid Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants
Phase 2 N=30 Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Thyroid Cancer
Primary: Objective Response Rate — 6 Participants
Phase 2 N=116 Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Phase 2 N=27 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Head and Neck Cancer
Primary: Objective Tumor Response Rate at 3, 6, and 12 Months — 0; 0; 12; 13 participants
Phase 2 N=35 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Overall Response Rate — 11 Participants
Phase 2 N=52 Nivolumab Plus Ipilimumab in Thyroid Cancer
Thyroid Cancer
Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants
Phase 2 N=20 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
Recurrent Thyroid Cancer · Stage IV Follicular Thyroid Cancer · Stage IV Papillary Thyroid Cancer
Primary: Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria — 10; 1 participants